DATUM

Artículos científicos

• Camarena ME, Theunissen P, Ruiz M, Ruiz-Orera J, Calvo-Serra B, Castelo R, Castro C, Sarobe P, Fortes P*, Perera-Bel J*, Albà MM*. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort. Sci Adv. 2024 Jul 12;10(28):eadn3628. PMID: 38985879

Comunicaciones en congresos

• IX Congreso de la Sociedad Española de Proteómica. Córdoba, 6-9 Febrero 2024. Póster
• Congreso EASL, Rotterdam, 22-24 de Febrero 2024, ponencia invitada
• RiboRed 2024. Bilbao 22-24 Mayo 2024, seleccionada
• Translacore Summer School. Milan 11-13 Sept 2024, seleccionada
• RNAlife network. El Escorial 18-10 Sept 2024, seleccionada
• Bridging RNA biology and therapy. Pamplona 9-11 Oct 2024, invitada
• IEEE BIBM – LncRNA´24 workshop. Lisbon 4th Dec 2024, invitada

Tesis relacionadas con este proyecto

• Mechanistic studies of lncRNAs relevant for HCC. Laura Prats-Mari. Fecha: Octubre 2024
• Ongoing: Nafiseh Khelghati y David Coronel

Trabajos de fin de máster relacionados con este proyecto

• Moving towards the development of microprotein-based cancer vaccines. Aurora Santamaría San Juan. Septiembre 2023.
• Análisis comparativo de proteínas canónicas y no canónicas en muestras de hepatocarcinoma y cáncer de mama. David Coronel. Septiembre 2024.

The DATUM project focused on studying microproteins — tiny proteins recently discovered that are essential for tumour growth. Identifying which ones play a key role is a major step forward, improving our understanding of cancer development and opening new avenues for medical applications.

These findings lay the groundwork for next-generation therapies designed to block the action of these microproteins, slowing disease progression. DATUM aims not only for more effective treatments but also for personalised therapies that enhance patients’ quality of life, offering a promising path in the fight against cancer.